drugset / Trial / NCT01791920

To Evaluate the Safety and Efficacy of Botulax® Are Not Inferior to Those of Botox® in the Treatment of Glabellar Lines

NCT01791920

Phase 3 Completed 262 enrolled Hugel
RandomizedParallel-groupDouble-blindTreatment

Summary

To compare the safety and efficacy of Botulax® with Botox® in the improvement of moderate to severe glabellar lines.

Timeline

Start
2011-08
Primary completion
2011-12
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 20 iu
Comparator letibotulinumtoxinA Protein / enzyme biologic 20 iu

Indications